Semax Without Prescription: The File FDA Says Is Missing

Buying Semax without prescription is the only way it is bought in the United States, and that sentence is true for a duller reason than most pages suggest. No prescription can be written for it, because there is no approved product to prescribe and no pharmacy route through which one could be compounded.

What fills the gap online is a claim that the compound is banned, or that it sits in a regulatory category it does not sit in. The record says something more specific and more useful, and it turns the question a reader is asking into one they can actually act on: not whether the substance is permitted, but which measurements exist for the material in front of them.

The research-use listing this page examines:

Semax without prescription: which of the three states it is in

A substance sold to the public in the United States sits in one of three positions, and it is worth naming all three because the differences between them are what the phrase in the heading actually turns on.

• An approved drug product, dispensed on prescription. A manufacturer has submitted a marketing application, the agency has reviewed the evidence, and a label exists that states an indication, a route and a quantity. Nothing of the kind exists for this peptide anywhere in the West.
• A preparation compounded from a bulk drug substance. A licensed pharmacy can compound from bulk substances under section 503A, but only where the substance is eligible, which in practice means appearing on the relevant list. This one appears on none of it, and the route is therefore closed rather than discouraged.
• Material sold under research-use terms. Supplied for laboratory work, not labelled or documented for human use, and not part of the drug supply chain. This is the channel that exists in practice, and everything a buyer can verify about it lives in the batch documentation rather than in any regulatory record.

Being in the third position is not the same as being prohibited, and the difference is worth insisting on because the alternative framing produces bad decisions in both directions. A reader who believes the compound is banned assumes any seller is criminal. A reader who believes research-use sale implies approval assumes any vial is medicine. Neither is right, and our explanation of what research-use supply actually means sets out the middle position in full.

The administrative history, in the order it happened

Four steps, and pages that garble this almost always garble it by reporting one of the middle steps as though it were the last one.

• It was nominated for use in compounding under section 503A, which is a request from an outside party rather than an agency initiative.
• It was placed in category 2 under the agency's interim policies while the evaluation proceeded. Category 2 is where substances go when FDA has identified significant safety risks in the material as nominated.
• The nomination was withdrawn by the nominator, which ends the process without producing a final determination either way.
• It appears in none of the three categories today. The category list updated on 14 May 2026 does not contain it at all, and the safety-risks page places it under the heading for substances nominated but withdrawn.

That is checkable in about a minute, and the check is worth running because it is falsifiable. The current category 2 contains six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. Open the list, read the six, and observe that this peptide is not one of them. So the claim that it was in category 2 is stale rather than false, and the claim that it is there now is simply wrong. The same distinction, on the neighbouring Russian nootropic peptide whose nomination followed the same path, is set out in our reading of the Selank regulatory record.

The sentence the agency wrote, and the four things it names

The safety-risks page carries a short assessment of this substance, listed under the name semax (heptapeptide), which is itself a confirmation of the seven-residue count. It reads, in full:

“Compounded drugs containing semax (heptapeptide) may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has no, or limited, safety-related information for proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans.”

Read as a scientific statement rather than a rhetorical one, it names four separate things, and three of them are measurements.

• Peptide-related impurities. Truncated, deleted and modified sequences generated during synthesis. These are what a reversed-phase chromatographic purity figure is for: related species elute at their own retention times and appear as separate peaks, and a stated specification gives the number something to be graded against.
• Aggregation. A physical state the peptide adopts in solution rather than a contaminant. This is the item most often waved away with a purity percentage, and it should not be. Reversed-phase conditions use organic solvent and ion-pairing agents that generally break non-covalent associations apart, so a high area percentage at 214 nm is not a statement about aggregate content. Size-exclusion chromatography is the method that addresses it, and it is absent from the certificates published in this market, including the good one discussed below.
• Route of administration. The concern is explicitly conditioned on route, which is why the same document treats identical impurity questions differently depending on how a preparation would be used.
• Human safety information. The one item on the list that no laboratory report can supply, no matter how many instruments it names.

Bacterial endotoxin belongs alongside those as a fourth measurement rather than inside them: it is a pyrogenic fragment of gram-negative bacterial cell wall, it survives sterilisation, and FDA treats its detection as a discipline of its own with dedicated questions and answers. A vial can be chemically immaculate and pyrogenic at the same time.

Which of those a published batch report can close

The supplier linked above publishes a four-page certificate for batch 30-05260628 under report number KVR-2026-E848E0, and it is more complete than this market's norm. Purity of 99.886 percent against a specification above 98 percent by reversed-phase chromatography with diode-array detection at 214 nm. Identity confirmed by liquid chromatography with mass spectrometry. Net content of 11.23 mg against an approximate 10 mg specification. Bacterial endotoxin below 0.20 EU/mL against a 0.5 EU/mL acceptance limit, by kinetic chromogenic LAL assay to USP Chapter 85, against an E. coli O111:B4 standard over a 0.01 to 1.0 EU/mL detection range across a 2.0 mL dilution volume, which is below 0.40 EU in total for the vial. A rapid two-day sterility screen returning no growth. Lead, arsenic, cadmium and mercury each below their acceptance limits by inductively coupled plasma mass spectrometry.

Against the agency's four items, that closes the impurity question for one batch, closes the identity question, and answers a pyrogen question the agency did not raise but a buyer should. It does not address aggregation, because no method on the document is capable of addressing it. It says nothing about route. And it produces no human safety data, which is the item the agency actually rested its conclusion on.

Two further reservations are worth stating, because the point of this site is not to flatter a good document. The endotoxin report lists its spike recovery as not applicable, which means no positive product control result appears to demonstrate that the sample matrix neither inhibited nor enhanced the reaction, and interference testing is a normal part of a compendial endotoxin determination. The sterility work is described by the laboratory itself as a rapid screen providing a preliminary assessment, with full compendial sterility testing under USP Chapter 71 noted as potentially required for regulatory purposes. Both of those qualifications come from the document rather than from us, which is a point in the document's favour.

Chemically the compound is not in dispute: a synthetic seven-residue peptide, PubChem CID 9811102, formula C37H51N9O10S, molecular weight 813.9, the ACTH(4-7) fragment with a Pro-Gly-Pro tail. Its Russian registration is a fact about a foreign regulatory system and not evidence by Western standards, and the mechanistic literature behind it is largely rodent work. Where the same regulatory shape appears on a compound with a far larger clinical literature behind it, our account of what approval would actually require shows what a completed evidence file looks like, and our note that a certificate is not a label makes the narrower point that applies here. Nothing on this page describes or implies human use.